MX2022004712A - Regimenes de dosificacion para tratar o prevenir enfermedades asociadas a c5. - Google Patents

Regimenes de dosificacion para tratar o prevenir enfermedades asociadas a c5.

Info

Publication number
MX2022004712A
MX2022004712A MX2022004712A MX2022004712A MX2022004712A MX 2022004712 A MX2022004712 A MX 2022004712A MX 2022004712 A MX2022004712 A MX 2022004712A MX 2022004712 A MX2022004712 A MX 2022004712A MX 2022004712 A MX2022004712 A MX 2022004712A
Authority
MX
Mexico
Prior art keywords
treating
preventing
associated diseases
dosing regimens
pozelimab
Prior art date
Application number
MX2022004712A
Other languages
English (en)
Inventor
George Yancopoulos
Feng Yang
Yi Zhang
John Davis
Albert Thomas Dicioccio
Olivier Harari
Kuan-Ju Lin
Andrew Rankin
Ronda Rippley
Jonathan Weyne
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2022004712A publication Critical patent/MX2022004712A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención proporciona regímenes de dosificación de anticuerpos anti-C5, tal como pozelimab, para tratar o prevenir enfermedades asociadas a C5, tal como la hemoglobinuria paroxística nocturna o la enfermedad CHAPLE.
MX2022004712A 2019-10-25 2020-10-23 Regimenes de dosificacion para tratar o prevenir enfermedades asociadas a c5. MX2022004712A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962926213P 2019-10-25 2019-10-25
US202062992330P 2020-03-20 2020-03-20
US202063019533P 2020-05-04 2020-05-04
PCT/US2020/056981 WO2021081277A1 (en) 2019-10-25 2020-10-23 Dosing regimens for treating or preventing c5-associated diseases

Publications (1)

Publication Number Publication Date
MX2022004712A true MX2022004712A (es) 2022-08-04

Family

ID=73449214

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022004712A MX2022004712A (es) 2019-10-25 2020-10-23 Regimenes de dosificacion para tratar o prevenir enfermedades asociadas a c5.

Country Status (10)

Country Link
US (1) US20210139573A1 (es)
EP (1) EP4048691A1 (es)
JP (1) JP2022553377A (es)
KR (1) KR20220087537A (es)
CN (1) CN115052889A (es)
AU (1) AU2020369581A1 (es)
CA (1) CA3153195A1 (es)
IL (1) IL291807A (es)
MX (1) MX2022004712A (es)
WO (1) WO2021081277A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023077053A2 (en) 2021-10-28 2023-05-04 Regeneron Pharmaceuticals, Inc. Crispr/cas-related methods and compositions for knocking out c5

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5981501A (en) 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
JP4656675B2 (ja) 1997-05-14 2011-03-23 ユニバーシティー オブ ブリティッシュ コロンビア 脂質小胞への荷電した治療剤の高率封入
EP2333062A1 (en) 2002-07-10 2011-06-15 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. RNA-interference by single-stranded RNA molecules
ITMI20021527A1 (it) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
CA2721333C (en) 2008-04-15 2020-12-01 Protiva Biotherapeutics, Inc. Novel lipid formulations for nucleic acid delivery
MY159396A (en) 2008-08-05 2016-12-30 Novartis Ag Compositions and methods for antibodies targeting complement protein c5
KR20230098713A (ko) 2009-06-10 2023-07-04 알닐람 파마슈티칼스 인코포레이티드 향상된 지질 조성물
MX366660B (es) 2013-03-14 2019-07-18 Alnylam Pharmaceuticals Inc Composiciones de arni contra el componente c5 del complemento y métodos para su uso.
WO2017212375A1 (en) 2016-06-07 2017-12-14 Novartis Ag Anti-c5 antibody for treating patients with complement c5 polymorphism
WO2017218515A1 (en) 2016-06-14 2017-12-21 Regeneron Pharmaceuticals, Inc. Anti-c5 antibodies and uses thereof
WO2018053039A1 (en) 2016-09-14 2018-03-22 The Usa, As Represented By The Secretary, Department Of Health & Human Services Methods of diagnosing and treating cd55 deficiency, hyperactivation of complement, angiopathic thrombosis and protein losing enteropathy (chaple), a newly identified orphan disease
CA3051389A1 (en) * 2017-01-31 2018-08-09 Kenji SHINOMIYA A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease

Also Published As

Publication number Publication date
CN115052889A (zh) 2022-09-13
JP2022553377A (ja) 2022-12-22
US20210139573A1 (en) 2021-05-13
AU2020369581A1 (en) 2022-04-21
EP4048691A1 (en) 2022-08-31
WO2021081277A1 (en) 2021-04-29
KR20220087537A (ko) 2022-06-24
IL291807A (en) 2022-06-01
CA3153195A1 (en) 2021-04-29

Similar Documents

Publication Publication Date Title
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
PH12020500177A1 (en) Bcma monoclonal antibody-drug conjugate
NZ753515A (en) Methods for treatment of cancer comprising tigit-binding agents
MX2022005253A (es) Anticuerpos neutralizantes de poliomavirus.
NZ738008A (en) Tigit-binding agents and uses thereof
EA201890305A1 (ru) Гуманизированные или химерные cd3-антитела
MY199530A (en) Anti-cd3epsilon antibodies
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
PH12018500578A1 (en) Methods of treating inflammatory diseases
CY1123275T1 (el) Μορια συνδεσης ειδικα για il-21 και χρησεις αυτων
MX2020008122A (es) Anticuerpos anti-pd-1.
EA201892225A1 (ru) АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ
BR112022003956A2 (pt) Anticorpos anti-cd73
TN2019000106A1 (en) Novel compounds for treating parasitic disease
EA202092508A1 (ru) Составы на основе антител к pd-l1 человека
EA202192786A1 (ru) Твердые формы (e)-3-[2-(2-тиенил)винил]-1h-пиразола
EA201990988A1 (ru) Антитела против chikv и пути их применения
MX2021006515A (es) Composiciones de methylobacterium para mejorar el rendimiento del maíz.
EA202191769A1 (ru) Тубулизины и конъюгаты белок-тубулизин
MX2022001841A (es) Anticuerpos contra ilt2 y uso de los mismos.
MX2021006865A (es) Anticuerpos anti-alfa-sinucleina y usos de estos.
MX2022004712A (es) Regimenes de dosificacion para tratar o prevenir enfermedades asociadas a c5.
JOP20220119A1 (ar) أجسام مضادة trem2 واستخداماتها
CR20220006A (es) Compuestos para tratar enfermedad respiratoria
MX2018014034A (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades.